As AI and machine learning (ML) continue to transform health care, the importance of effective post-market surveillance mechanisms becomes clear. With nearly 1,000 AI-enabled medical devices approved as of 2024, ranging from predictive glucose monitors to AI-equipped smartwatches, there is no denying the potential for innovation. However, the same technologies that offer breakthroughs can also perpetuate systemic biases and create real-world challenges that aren’t always detected during premarket testing. The article highlights why continuous real-world monitoring is essential to catch and address biases and edge cases as they emerge.
Greenlight is uniquely positioned to help close the post-market monitoring gap by offering real-time, patient-mediated health data that continuously feeds into research, supporting AI/ML-based innovations. By ensuring data liquidity, Greenlight helps maintain the ongoing flow of high-quality, diverse datasets needed to evaluate real-world performance, identify biases, and enable iterative improvements. As healthcare systems increasingly adopt AI/ML solutions, Greenlight’s technology ensures that researchers and regulators have the right data at the right time to support effective, bias-free decision-making and safeguard patient outcomes.
Read the full article: We Need More Robust Post-Market Surveillance For Health Care AI – HealthAffairs.org
